Clinical Trial Update: Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients [NA]

View source ↗

Summary

A clinical trial exploring whether dipeptide alanyl glutamine affects postoperative insulin resistance in patients with colon cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Dipeptide alanyl glutamine (L-alanyl-L-glutamine)

Snippet

Sponsor: Medical Center Alkmaar | Conditions: Colon Carcinoma | NA | Status: UNKNOWN